IDEOGEN Group GmbH has been appointed as the exclusive partner for Omisirge (omidubicel-onlv) by Ayrmid Ltd. (Gamida Cell Inc.) for a managed access programme across 55 markets in Europe, excluding Greece and Cyprus, the Middle East and North Africa, and the Commonwealth of Independent States.

Ideogen Group is a Swiss pharmaceutical group, providing global access to specialty medicines for unmet medical needs. We specialize in the commercialization of specialty medicines across multiple geographies with challenging and evolving healthcare dynamics. With the resources to handle activities ranging from early access and name patient programs through licensed medicines life cycle management; we focus on contributing to unmet needs by offering healthcare providers access to unique treatment alternatives for medical challenges patients face today. Since 2013 we have modelled our groups activities around underserved treatment options. We solve the problems that matter and have an impact on patients and prescribers alike. We approach each of our partnerships with transparency, loyalty, and a sense of urgency to resolve challenges aligned with our commercial capabilities. We believe in nurturing the awareness around innovative therapies, as they meet real needs of society today.

Founded 2012